All In Biotech

Drug Trial Radar · NCT06644183

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

A Phase 1/2, Open Label, Study of Roginolisib (IOA-244), an Orally Bioavailable, Selective PI3Kδ Inhibitor in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) in Combination With Venetoclax and Rituximab

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Mar 19, 2025

Primary completion

Oct 1, 2028

Study completion Oct 1, 2032

Sponsor

Lead sponsor
Jennifer R. Brown, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody)

Conditions

  • Leukemia
  • Relapsed Leukemia
  • Chronic Lymphocytic Leukemia
  • Relapsed Cancer
  • Refractory Leukemia

Interventions

  • RoginolisibDrug

    Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.

  • VenetoclaxDrug

    B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.

  • RituximabDrug

    Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Undetectable Minimal Residual Disease(uMRD) rate by ClonoSEQ assayTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.